Cancer organoids: A platform in basic and translational research

Xin Ma; Qin Wang; Guozheng Li; Hui Li; Shouping Xu; Da Pang

doi:10.1016/j.gendis.2023.02.052

您当前的位置：

首页 >

文章列表页 >

Cancer organoids: A platform in basic and translational research

Review article | 更新时间：2024-02-04

- Cancer organoids: A platform in basic and translational research
- Cancer organoids: A platform in basic and translational research
- Genes & Diseases 2024年11卷第2期
- 作者机构：
  
  1. Department of Pharmacology (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), College of Pharmacy of Harbin Medical University,Heilongjiang,Harbin,China,150086
  2. Department of Breast Surgery, Harbin Medical University Cancer Hospital,Heilongjiang,Harbin,China,150081
  3. Heilongjiang Academy of Medical Sciences,Heilongjiang,Harbin,China,150086
  4. Sino-Russian Medical Research Center, Harbin Medical University Cancer Hospital,Heilongjiang,Harbin,China,150081
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2023.02.052
  中图分类号：
- 纸质出版日期：2024，
  
  网络出版日期：2024-3-1，
扫描看全文
Xin Ma, Qin Wang, Guozheng Li, 等. Cancer organoids: A platform in basic and translational research[J]. Genes & Diseases, 2024,11(2).

Xin Ma, Qin Wang, Guozheng Li, et al. Cancer organoids: A platform in basic and translational research[J]. Genes & Diseases, 2024,11(2).
Xin Ma, Qin Wang, Guozheng Li, 等. Cancer organoids: A platform in basic and translational research[J]. Genes & Diseases, 2024,11(2). DOI： 10.1016/j.gendis.2023.02.052.

Xin Ma, Qin Wang, Guozheng Li, et al. Cancer organoids: A platform in basic and translational research[J]. Genes & Diseases, 2024,11(2). DOI： 10.1016/j.gendis.2023.02.052.

摘要

Abstract

n accumulation of previous work has established organoids as good preclinical models of human tumors

facilitating translation from basic research to clinical practice. They are changing the paradigm of preclinical cancer research because they can recapitulate the heterogeneity and pathophysiology of human cancers and more closely approximate the complex tissue environment and structure found in clinical tumors than

in vitro

cell lines and animal models. However

the potential applications of cancer organoids remain to be comprehensively summarized. In the review

we firstly describe what is currently known about cancer organoid culture and then discuss in depth the basic mechanisms

including tumorigenesis and tumor metastasis

and describe recent advances in patient-derived tumor organoids (PDOs) for drug screening and immunological studies. Finally

the present challenges faced by organoid technology in clinical practice and its prospects are discussed. This review highlights that organoids may offer a novel therapeutic strategy for cancer research.

关键词

Keywords

Drug assaysImmunotherapyMechanism researchOrganoidsPrecision medicine

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy

The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy

Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics